The fact that only some but not all ATR-/CHK1-inhibitors elicited POLD1-dependent effects might be ascribable to the additional unspecific inhibition of other targets inherent to chemical inhibitors along with the heterogeneous genotype of the tested CRC lines. The gene discussed is ATR; the disease is colorectal carcinoma.